Pimavanserin: Potential Treatment For Dementia-Related Psychosis
| Autor: | Pierre N. Tariot, James C. Norton, Jeffrey L. Cummings, James M. Youakim, Srdjan Stankovic, Clive Ballard, Erin P. Foff, Randy Owen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Psychosis Parkinson's disease Neurology Pimavanserin Subgroup analysis Review Placebo Severity of Illness Index frontotemporal dementia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Piperidines Alzheimer Disease Internal medicine medicine Dementia Humans Urea psychosis Clinical Trials as Topic 030214 geriatrics business.industry Dementia with Lewy bodies Parkinson Disease medicine.disease Mental Status and Dementia Tests 3. Good health Treatment Outcome chemistry Psychotic Disorders Serotonin 5-HT2 Receptor Antagonists Parkinson’s disease business dementia with Lewy bodies Alzheimer’s disease 030217 neurology & neurosurgery |
| Zdroj: | The Journal of Prevention of Alzheimer's Disease |
| ISSN: | 2426-0266 |
| Popis: | Psychosis is common across dementia types with a prevalence of 20% to 70%. Currently, no pharmacologic treatment is approved for dementia-related psychosis. Atypical antipsychotics are frequently used to treat these disorders, despite significant safety concerns. Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved in the U.S. for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Patients in the pimavanserin group experienced a significant (p=0.001) improvement in Scale for the Assessment of Positive Symptoms - Parkinson's disease (SAPS-PD) scores vs. placebo. In a subgroup analysis of patients with cognitive impairment (MMSE score ≥21 but ≤24), the observed improvement on the SAPS-PD with pimavanserin (N=50) was also significant (p=0.002) and larger than in the overall study population without an adverse effect on cognition. In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0.045) improved psychosis at Week 6 vs. placebo on the NPI-NH Psychosis Score (PS). In a prespecified subgroup of patients with a baseline NPI-NH PS ≥12, a substantively larger treatment effect (p=0.011) was observed vs. participants with NPI-NH PS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink